vs
Side-by-side financial comparison of Agilent Technologies (A) and Enhabit, Inc. (EHAB). Click either name above to swap in a different company.
Agilent Technologies is the larger business by last-quarter revenue ($1.8B vs $270.4M, roughly 6.6× Enhabit, Inc.). Agilent Technologies runs the higher net margin — 17.0% vs -14.3%, a 31.3% gap on every dollar of revenue. On growth, Agilent Technologies posted the faster year-over-year revenue change (7.0% vs 4.7%). Agilent Technologies produced more free cash flow last quarter ($175.0M vs $3.3M). Over the past eight quarters, Agilent Technologies's revenue compounded faster (6.9% CAGR vs 1.5%).
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emissi...
Enhabit, Inc., is a Dallas, Texas-based provider of home health and hospice services. The company operates 255 home health and 110 hospice locations in 34 states with a concentration in Texas, Alabama, Florida, Georgia, Oklahoma and Mississippi. Enhabit is the fourth-largest provider of home health services in the United States and is a leading provider of hospice services. The company was formed in 2022 when Encompass Health spun off its home health and hospice business.
A vs EHAB — Head-to-Head
Income Statement — Q1 2026 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $1.8B | $270.4M |
| Net Profit | $305.0M | $-38.7M |
| Gross Margin | 52.6% | — |
| Operating Margin | 19.6% | -12.3% |
| Net Margin | 17.0% | -14.3% |
| Revenue YoY | 7.0% | 4.7% |
| Net Profit YoY | -4.1% | 15.9% |
| EPS (diluted) | $1.07 | $-0.76 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.9B | $270.4M | ||
| Q3 25 | $1.7B | $263.6M | ||
| Q2 25 | $1.7B | $266.1M | ||
| Q1 25 | $1.7B | $259.9M | ||
| Q4 24 | $1.7B | $258.2M | ||
| Q3 24 | $1.6B | $253.6M | ||
| Q2 24 | $1.6B | $260.6M |
| Q1 26 | $305.0M | — | ||
| Q4 25 | $434.0M | $-38.7M | ||
| Q3 25 | $336.0M | $11.1M | ||
| Q2 25 | $215.0M | $5.2M | ||
| Q1 25 | $318.0M | $17.8M | ||
| Q4 24 | $351.0M | $-46.0M | ||
| Q3 24 | $282.0M | $-110.2M | ||
| Q2 24 | $308.0M | $-200.0K |
| Q1 26 | 52.6% | — | ||
| Q4 25 | 53.2% | — | ||
| Q3 25 | 51.1% | — | ||
| Q2 25 | 51.9% | — | ||
| Q1 25 | 53.5% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 54.2% | — | ||
| Q2 24 | 54.4% | — |
| Q1 26 | 19.6% | — | ||
| Q4 25 | 23.8% | -12.3% | ||
| Q3 25 | 20.7% | 6.4% | ||
| Q2 25 | 18.0% | 6.3% | ||
| Q1 25 | 22.4% | 6.1% | ||
| Q4 24 | 24.0% | -16.0% | ||
| Q3 24 | 21.1% | -38.6% | ||
| Q2 24 | 23.1% | 4.3% |
| Q1 26 | 17.0% | — | ||
| Q4 25 | 23.3% | -14.3% | ||
| Q3 25 | 19.3% | 4.2% | ||
| Q2 25 | 12.9% | 2.0% | ||
| Q1 25 | 18.9% | 6.8% | ||
| Q4 24 | 20.6% | -17.8% | ||
| Q3 24 | 17.9% | -43.5% | ||
| Q2 24 | 19.6% | -0.1% |
| Q1 26 | $1.07 | — | ||
| Q4 25 | $1.53 | $-0.76 | ||
| Q3 25 | $1.18 | $0.22 | ||
| Q2 25 | $0.75 | $0.10 | ||
| Q1 25 | $1.11 | $0.35 | ||
| Q4 24 | $1.23 | $-0.92 | ||
| Q3 24 | $0.97 | $-2.20 | ||
| Q2 24 | $1.05 | $0.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.8B | $43.6M |
| Total DebtLower is stronger | $3.0B | $426.0M |
| Stockholders' EquityBook value | $6.9B | $534.0M |
| Total Assets | $12.8B | $1.2B |
| Debt / EquityLower = less leverage | 0.44× | 0.80× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | $43.6M | ||
| Q3 25 | $1.5B | $56.9M | ||
| Q2 25 | $1.5B | $37.1M | ||
| Q1 25 | $1.5B | $39.5M | ||
| Q4 24 | $1.3B | $28.4M | ||
| Q3 24 | $1.8B | $45.7M | ||
| Q2 24 | $1.7B | $28.5M |
| Q1 26 | $3.0B | — | ||
| Q4 25 | $3.0B | $426.0M | ||
| Q3 25 | $3.4B | $441.5M | ||
| Q2 25 | $3.3B | $456.9M | ||
| Q1 25 | $3.3B | $467.3M | ||
| Q4 24 | $3.3B | $492.6M | ||
| Q3 24 | $2.1B | $502.9M | ||
| Q2 24 | $2.1B | $512.7M |
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.7B | $534.0M | ||
| Q3 25 | $6.4B | $566.8M | ||
| Q2 25 | $6.1B | $552.4M | ||
| Q1 25 | $6.0B | $543.2M | ||
| Q4 24 | $5.9B | $523.5M | ||
| Q3 24 | $5.9B | $566.1M | ||
| Q2 24 | $6.2B | $674.3M |
| Q1 26 | $12.8B | — | ||
| Q4 25 | $12.7B | $1.2B | ||
| Q3 25 | $12.2B | $1.2B | ||
| Q2 25 | $12.2B | $1.2B | ||
| Q1 25 | $11.9B | $1.2B | ||
| Q4 24 | $11.8B | $1.2B | ||
| Q3 24 | $11.0B | $1.3B | ||
| Q2 24 | $10.9B | $1.4B |
| Q1 26 | 0.44× | — | ||
| Q4 25 | 0.45× | 0.80× | ||
| Q3 25 | 0.53× | 0.78× | ||
| Q2 25 | 0.55× | 0.83× | ||
| Q1 25 | 0.56× | 0.86× | ||
| Q4 24 | 0.57× | 0.94× | ||
| Q3 24 | 0.36× | 0.89× | ||
| Q2 24 | 0.34× | 0.76× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $268.0M | $4.4M |
| Free Cash FlowOCF − Capex | $175.0M | $3.3M |
| FCF MarginFCF / Revenue | 9.7% | 1.2% |
| Capex IntensityCapex / Revenue | 5.2% | 0.4% |
| Cash ConversionOCF / Net Profit | 0.88× | — |
| TTM Free Cash FlowTrailing 4 quarters | $993.0M | $65.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $268.0M | — | ||
| Q4 25 | $545.0M | $4.4M | ||
| Q3 25 | $362.0M | $37.8M | ||
| Q2 25 | $221.0M | $10.6M | ||
| Q1 25 | $431.0M | $17.9M | ||
| Q4 24 | $481.0M | $-4.1M | ||
| Q3 24 | $452.0M | $28.4M | ||
| Q2 24 | $333.0M | $9.6M |
| Q1 26 | $175.0M | — | ||
| Q4 25 | $452.0M | $3.3M | ||
| Q3 25 | $259.0M | $36.2M | ||
| Q2 25 | $107.0M | $8.7M | ||
| Q1 25 | $334.0M | $17.6M | ||
| Q4 24 | $388.0M | $-4.7M | ||
| Q3 24 | $360.0M | $27.7M | ||
| Q2 24 | $230.0M | $8.9M |
| Q1 26 | 9.7% | — | ||
| Q4 25 | 24.3% | 1.2% | ||
| Q3 25 | 14.9% | 13.7% | ||
| Q2 25 | 6.4% | 3.3% | ||
| Q1 25 | 19.9% | 6.8% | ||
| Q4 24 | 22.8% | -1.8% | ||
| Q3 24 | 22.8% | 10.9% | ||
| Q2 24 | 14.6% | 3.4% |
| Q1 26 | 5.2% | — | ||
| Q4 25 | 5.0% | 0.4% | ||
| Q3 25 | 5.9% | 0.6% | ||
| Q2 25 | 6.8% | 0.7% | ||
| Q1 25 | 5.8% | 0.1% | ||
| Q4 24 | 5.5% | 0.2% | ||
| Q3 24 | 5.8% | 0.3% | ||
| Q2 24 | 6.5% | 0.3% |
| Q1 26 | 0.88× | — | ||
| Q4 25 | 1.26× | — | ||
| Q3 25 | 1.08× | 3.41× | ||
| Q2 25 | 1.03× | 2.04× | ||
| Q1 25 | 1.36× | 1.01× | ||
| Q4 24 | 1.37× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.08× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
A
| Service Other | $525.0M | 29% |
| Chemicaland Energy Market | $422.0M | 23% |
| Agilent Cross Lab | $273.0M | 15% |
| Environmentaland Forensics Market | $177.0M | 10% |
| Food Market | $166.0M | 9% |
| Academiaand Government Market | $130.0M | 7% |
| Applied Markets | $98.0M | 5% |
EHAB
| Third Party Payor Medicare | $111.6M | 41% |
| Third Party Payor Medicare Advantage | $67.5M | 25% |
| Hospice Segment | $63.6M | 24% |
| Third Party Payor Managed Care | $24.9M | 9% |
| Third Party Payor Medicaid | $1.7M | 1% |
